Skip to content
Nitto Avecia logo — Comprehensive oligo solutions, from concept to commercial.

Nitto Avecia

Comprehensive oligo solutions, from concept to commercial.

Founded 1995 United States Milford, United States 601 employees Biotechnology, Manufacturing +1

General Information

Company Name Nitto Avecia
Founded Year 1995
Location United States Milford, United States
Employees 601
Industries Biotechnology, Manufacturing, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with Nitto Avecia. To contact Nitto Avecia, visit avecia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nitto Avecia compare?

A PDF of Nitto Avecia and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nitto Avecia soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Nitto Avecia

Nitto Avecia is a leading player in the oligonucleotide market, offering comprehensive solutions for the development and production of these therapeutics. With over 25 years of experience, the company has positioned itself as a preferred partner for pharmaceutical innovators aiming to revolutionize treatment across various diseases. Partnering with Nitto Avecia Pharma Services, the company is the first CMO to provide an end-to-end oligonucleotide solution, demonstrating expertise in handling the entire process from drug substance through drug product manufacturing. This inclusive approach allows for flexibility, reliability, and consistent quality. Founded in 1995, Nitto Avecia operates in the industries of Biotechnology, Manufacturing, and Pharmaceuticals, with its headquarters in the United States. Currently, there is no publicly available information on the last investment or the investors involved. The company's dedication to providing a comprehensive oligo solution is testament to its potential for growth and impact in the biotech and pharma sectors.

Business keywords: oligonucleotides, therapeutics, pharmaceutical, CMO, drug development, clinical trials, biotechnology-based medicines, process validation, analytical services, stability services, drug substance, drug product, clinical development

No funding data available for Nitto Avecia yet.

Nitto Avecia Alternatives & Competitors

View All Alternatives
Nitto Avecia vs
CatSci Ltd
CatSci Ltd United Kingdom

Excellence in Medicines Development

Growth
100 employees
Biopharma, Biotechnology
Nitto Avecia vs

Fostering Value through Innovation

155 employees
Biotechnology, Manufacturing
Nitto Avecia vs

Hacemos ciencia, medimos fármacos, potenciamos proyectos

41 employees
Biopharma, Biotechnology

FAQ About Nitto Avecia

Comprehensive oligo solutions, from concept to commercial.
Nitto Avecia was founded in 1995.
Nitto Avecia is headquartered in Milford, United States.
Nitto Avecia operates in Biotechnology, Manufacturing and Pharmaceutical. Its work centres on oligonucleotides, therapeutics, pharmaceutical and CMO.
Nitto Avecia has approximately 601 employees.
Top alternatives and competitors to Nitto Avecia include CatSci Ltd, Cerbios-Pharma SA, pharmometrica, ForDoz Pharma Corp, Odyssey Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nitto Avecia and CatSci Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nitto Avecia, https://bouncewatch.com/company/nitto-avecia, updated 5 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout